

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Kalydeco (ivacaftor)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Kalydeco (ivacaftor)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Kalydeco (ivacaftor) may be approved if the following are met:

- I. Individual has a diagnosis of cystic fibrosis (CF); **AND**
- II. Individual is 2 years of age or older; **AND**
- III. A copy of the CF mutation analysis test results must be provided; **AND**
- IV. Individual has a mutation-positive result in the cystic fibrosis transmembrane conductance regulator (CFTR) gene with **one** of the following mutation types:
 - A. G551D; **OR**
 - B. G1244E; **OR**
 - C. G1349D; **OR**
 - D. G178R; **OR**
 - E. G551S; **OR**
 - F. S1251N; **OR**
 - G. S1255P; **OR**
 - H. S549N; **OR**
 - I. S549R; **OR**
 - J. R117H; **OR**
 - K. E193K; **OR**
 - L. F1052V; **OR**
 - M. D1152H; **OR**
 - N. G1069R; **OR**
 - O. D579G; **OR**
 - P. K1060T; **OR**
 - Q. S945L; **OR**
 - R. R74W; **OR**
 - S. A1067T; **OR**
 - T. R1070W; **OR**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

- U. D110H; **OR**
- V. R347H; **OR**
- W. D1270N; **OR**
- X. P67L; **OR**
- Y. D110E; **OR**
- Z. R352Q; **OR**
- AA. E56K; **OR**
- BB. A455E; **OR**
- CC. L206W; **OR**
- DD. F1074L; **OR**
- EE. R117C; **OR**
- FF. S977F; **OR**
- GG. R1070Q; **OR**
- HH. 2789+5G→A; **OR**
- II. 3272-26A→G; **OR**
- JJ. 3849+10kbC→T; **OR**
- KK. 711+3A→G; **OR**
- LL. E831X.

Kalydeco (ivacaftor) monotherapy, without concurrent use of lumacaftor, may not be approved for the following:

- I. Individual is homozygous for F508del mutation in the CFTR gene.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 9, 2017.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.